Clinical Trials
6 trialsNCT03547700 2026-05-06
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT04079738 2023-09-13
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT02898259 2022-09-26
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Case Comprehensive Cancer Center
Phase 1/2 Terminated
NCT02993094 2020-11-30
Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 1/2 Terminated
NCT03492138 2020-05-29
Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Icahn School of Medicine at Mount Sinai
Phase 1/2 Terminated
NCT02447887 2019-09-26
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Fox Chase Cancer Center
Phase 1/2 Terminated